After over a decade spent building Incyte up into a competitive commercial drugmaker, the company’s longtime CEO Hervé ...

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

Madrigal has set a list price of the Rezdiffra of $47,400 per year, ahead of any discounts or rebates, which lies within the $39,600 to $50,100 range that the influential Institute for Clinical ...

The non-alcoholic steatohepatitis (NASH) clinical trials market is estimated to generate a market size of USD 2.96 billion in ...